A002620 Stock Overview
Manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Jeil Pharma Holdings Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,920.00 |
| 52 Week High | ₩12,380.00 |
| 52 Week Low | ₩7,200.00 |
| Beta | 1.16 |
| 1 Month Change | -6.27% |
| 3 Month Change | -11.01% |
| 1 Year Change | -32.37% |
| 3 Year Change | -51.85% |
| 5 Year Change | -53.41% |
| Change since IPO | 273.58% |
Recent News & Updates
Recent updates
Estimating The Intrinsic Value Of Jeil Pharma Holdings Inc (KRX:002620)
Dec 09
Is Jeil Pharma Holdings Inc (KRX:002620) A Smart Choice For Dividend Investors?
Mar 25These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27What Percentage Of Jeil Pharma Holdings Inc (KRX:002620) Shares Do Insiders Own?
Jan 23
Jeil Pharma Holdings (KRX:002620) Has Compensated Shareholders With A 56% Return On Their Investment
Dec 28Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23Shareholder Returns
| A002620 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.9% | 1.8% | -2.1% |
| 1Y | -32.4% | 4.3% | -9.0% |
Return vs Industry: A002620 underperformed the KR Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: A002620 underperformed the KR Market which returned -9% over the past year.
Price Volatility
| A002620 volatility | |
|---|---|
| A002620 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A002620 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A002620's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 35 | Seung-Soo Han | www.jeilpharm.co.kr |
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives.
Jeil Pharma Holdings Inc Fundamentals Summary
| A002620 fundamental statistics | |
|---|---|
| Market cap | ₩121.58b |
| Earnings (TTM) | -₩41.48b |
| Revenue (TTM) | ₩778.79b |
0.2x
P/S Ratio-2.9x
P/E RatioIs A002620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A002620 income statement (TTM) | |
|---|---|
| Revenue | ₩778.79b |
| Cost of Revenue | ₩575.67b |
| Gross Profit | ₩203.11b |
| Other Expenses | ₩244.59b |
| Earnings | -₩41.48b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.70k |
| Gross Margin | 26.08% |
| Net Profit Margin | -5.33% |
| Debt/Equity Ratio | 35.1% |
How did A002620 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield-2%
Payout RatioDoes A002620 pay a reliable dividends?
See A002620 dividend history and benchmarks| Jeil Pharma Holdings dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 18 2025 |
| Days until Ex dividend | 2 days |
| Days until Dividend pay date | 114 days |
Does A002620 pay a reliable dividends?
See A002620 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 22:00 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jeil Pharma Holdings Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|